


HEDIS Provider Tip Sheet



AAB Measure Description¹

Assesses the percentage of episodes for members 3 months of age and older with a diagnosis of acute bronchitis/bronchiolitis that did not result in an antibiotic dispensing event. A higher rate indicates appropriate treatment for bronchitis/bronchiolitis (i.e., the percentage of episodes that were not prescribed an antibiotic).

Why is AAB Important?¹

Acute bronchitis/bronchiolitis almost always gets better on its own; therefore, individuals without other health problems should not be prescribed an antibiotic. Ensuring the appropriate use of antibiotics for individuals with acute bronchitis/bronchiolitis will help them avoid harmful side-effects and possible resistance to antibiotics over time.

Antibiotic resistance is a major health concern in the United States, with 2.8 million antibiotic-resistant infections and 35,000 deaths occurring annually.

Best Practices

- ✓ Avoid prescribing an antibiotic unless there is a bacterial etiology.
- ✓ Members that have asthma and diabetes diagnosis, symptoms such as fever, cough and wheezing and tobacco use are included for this HEDIS measure.
- ✓ This measure is based on episodes; members may have multiple episodes.
- ✓ CDC offers materials and tools about antibiotic resistance, appropriate prescribing and use for common infections.

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Source: https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/

² Source: HEDIS MY 2025 Tech Specs Manual Vol. 2



HEDIS Provider Tip Sheet

Numerator Compliance²

Dispensed prescription for an antibiotic medication on or 3 days after the episode date.

Refer to the next page for the list of medications.

Data Collection Method²

Administrative (Claims)



Trillium Percentages/NCQA National Averages¹

AAB	Measurement Year	Trillium	NCQA National Average
Total	2023	45.21	62.56
	2022	-	62.2

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

¹ Source: https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/

² Source: HEDIS MY 2025 Tech Specs Manual Vol. 2



HEDIS Provider Tip Sheet

AAB Numerator Medications²

Description	Prescription		
Aminoglycosides	Amikacin Gentamicin	Streptomycin Tobramycin	
Aminopenicillins	Amoxicillin	Ampicillin	
Beta-lactamase inhibitors	Amoxicillin-clavulanate Ampicillin-sulbactam	Piperacillin-tazobactam	
First-generation cephalosporins	Cefadroxil Cefazolin	Cephalexin	
Fourth-generation cephalosporins	Cefepime		
Lincomycin derivatives	Clindamycin	Lincomycin	
Macrolides	Azithromycin Clarithromycin	Erythromycin	
Miscellaneous antibiotics	Aztreonam Chloramphenicol Dalfopristin-quinupristin Daptomycin	Linezolid Metronidazole Vancomycin	
Natural penicillins	Penicillin G benzathine Penicillin G benzathine-procaine Penicillin G potassium	Penicillin G procaine Penicillin G sodium Penicillin V potassium	
Penicillinase resistant penicillins	Dicloxacillin Nafcillin	Oxacillin	
Quinolones	Ciprofloxacin Gemifloxacin Levofloxacin	Moxifloxacin Ofloxacin	
Rifamycin derivatives	Rifampin		
Second-generation cephalosporin	Cefaclor Cefotetan Cefoxitin	Cefprozil Cefuroxime	
Sulfonamides	Sulfadiazine	Sulfamethoxazole-trimethoprim	
Tetracyclines	Doxycycline Minocycline	Tetracycline	
Third-generation cephalosporins	Cefdinir Cefixime Cefotaxime	Cefpodoxime Ceftazidime Ceftriaxone	
Urinary anti-infectives	Fosfomycin Nitrofurantoin	Nitrofurantoin macrocrystals- monohydrate Trimethoprim	
Tetracyclines	Doxycycline Minocycline	Tetracycline	

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

¹ Source: https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/

² Source: HEDIS MY 2025 Tech Specs Manual Vol. 2